The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
Vincenzo Quagliariello(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Nicola Maurea(Cancer Institute (WIA)), Lucia Altucci(Biogem), Andreina Carbone(Azienda Ospedaliera Universitaria Università degli Studi della Campania Luigi Vanvitelli), Antônio Barbieri, Andrea Paccone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Domenica Rea(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Mariarosaria Conte(University of Campania "Luigi Vanvitelli"), M. Monti(Federico II University Hospital), Gerardo Botti(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Maria Laura Canale(Ospedale Versilia), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")
Cited by 368
Related Papers
Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018
|Cell Death and Differentiation|2018|6.6k
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Cancer classification using the Immunoscore: a worldwide task force
|Journal of Translational Medicine|2012|803